Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

CD4 T cells in tumor immunity.

Gerloni M, Zanetti M.

Springer Semin Immunopathol. 2005 Jun;27(1):37-48. Epub 2005 Mar 15. Review.

PMID:
15965712
2.

The role of CD4+ T cell responses in antitumor immunity.

Pardoll DM, Topalian SL.

Curr Opin Immunol. 1998 Oct;10(5):588-94. Review.

PMID:
9794842
3.

MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.

Chhabra A.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):344-52.

PMID:
19807670
4.

MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.

Topalian SL.

Curr Opin Immunol. 1994 Oct;6(5):741-5. Review.

PMID:
7826529
5.
6.

T cell-mediated immune responses in melanoma: implications for immunotherapy.

Wang RF, Zeng G, Johnston SF, Voo K, Ying H.

Crit Rev Oncol Hematol. 2002 Jul;43(1):1-11. Review.

PMID:
12098604
7.

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.

Cancer Res. 2005 Aug 1;65(15):6984-9.

9.
10.

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Knutson KL, Disis ML.

Cancer Immunol Immunother. 2005 Aug;54(8):721-8. Epub 2005 Jan 27. Review.

PMID:
16010587
11.

Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.

Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D'Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F.

Clin Cancer Res. 2008 Nov 15;14(22):7292-303. doi: 10.1158/1078-0432.CCR-08-0832. Epub 2008 Oct 30.

12.

MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.

Cancer Res. 2007 May 1;67(9):4499-506.

14.

Multiple roles for CD4+ T cells in anti-tumor immune responses.

Kennedy R, Celis E.

Immunol Rev. 2008 Apr;222:129-44. doi: 10.1111/j.1600-065X.2008.00616.x. Review.

PMID:
18363998
15.

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.

Cancer Res. 2006 Jan 15;66(2):1147-54.

16.

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.

Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E.

Clin Cancer Res. 2005 Aug 1;11(15):5566-71.

17.

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Maccalli C, Scaramuzza S, Parmiani G.

Cancer Immunol Immunother. 2009 May;58(5):801-8. doi: 10.1007/s00262-008-0635-x. Epub 2008 Dec 17. Review.

PMID:
19089424
19.

The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice.

Gerloni M, Castiglioni P, Zanetti M.

J Immunol. 2005 Nov 15;175(10):6551-9.

20.

Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients.

Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillère B.

J Immunol. 2008 Jul 1;181(1):431-9.

Supplemental Content

Support Center